AR018593A1 - COMPUESTOS TRICICLICOS SUSTITUIDOS, FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE, USO DE DICHO COMPUESTO PARA FABRICAR UN MEDICAMENTO uTIL PARA INHIBIR SELECTIVAMENTE SPLA2 Y ALIVIAR EFECTOS PATOLoGICOS DE ENFERMEDADES RELACIONADAS - Google Patents
COMPUESTOS TRICICLICOS SUSTITUIDOS, FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE, USO DE DICHO COMPUESTO PARA FABRICAR UN MEDICAMENTO uTIL PARA INHIBIR SELECTIVAMENTE SPLA2 Y ALIVIAR EFECTOS PATOLoGICOS DE ENFERMEDADES RELACIONADASInfo
- Publication number
- AR018593A1 AR018593A1 ARP990101771A ARP990101771A AR018593A1 AR 018593 A1 AR018593 A1 AR 018593A1 AR P990101771 A ARP990101771 A AR P990101771A AR P990101771 A ARP990101771 A AR P990101771A AR 018593 A1 AR018593 A1 AR 018593A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- hydrogen
- carbon
- sulfur
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describen nuevos compuestos tricíclicos y el uso de los mismos para inhibir la liberacion de ácidos grasos inducida por sPLA2 para el tratamientode trastornos como el choque séptico. Dichos compuestos tienen la formula (I), en la que: Z es ciclohexenilo o fenilo, R20 se selecciona de grupo (a), (b)y (c), donde: (a) es alquilo C5-20, alquenilo C5-20, alquinilo C-5-20, radicales carbocíclicos o radicales heterocíclicos, o (b) es un miembro de (a)sustituido con uno o más sustituyentes no interferentes, seleccionados independientemente; o (c) es el grupo -(L)-R80; siendo -(L)- un grupo de uniondivalente de 1 a 12 átomos, seleccionados de carbono, hidrogeno, oxígeno, nitrogeno y azufre; seleccionándose la combinacion de átomos en -(L)- delgrupo compuesto por (i) solo carbono e hidrogeno, (ii) solo azufre, (iii) solo un oxígeno, (iv) solo uno o dos nitrogenos e hidrogeno, (v) carbono, hidrogeno ysolo un azufre, y (vi) un carbono, hidrogeno y solo oxígeno; y siendo R80 un grupo seleccionado de (a) o (b); R21 es un sustituyente no interferente en elque f es 1-3; R1 es -NHNH2, -NH2 o -CONH2; R2 se selecciona del grupo formado por -OH y -O(CH2)tR5, donde R5 es H, -CN, -NH2, -CONH2, -CONR9R10, -NHSO2R15,-CONHSO2R15, siendo R15 -alquilo C1-6 o -CF3, fenilo o fenilo sustituido con -CO2H o -CO2-alquilo C1-4; y -(La)- (grupo ácido), siendo -(La)-un grupo de unionde ácido que tiene una longitud de grupo de union de ácido de 1 a 7, y t es 1-5; R3 se selecciona de sustituyentes no interferentes, radicales carbocíclicos,carbocíclicos sustituidos con sustituyentes no interferentes, radicales heterocíclicos y radicales heterocíclicos sustituidos con sustituyentes nointerferentes; o uno de sus racematos, solvatos, tautomeros, isomeros opticos, derivados profármacos o sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6232898A | 1998-04-17 | 1998-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018593A1 true AR018593A1 (es) | 2001-11-28 |
Family
ID=22041763
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101770A AR018186A1 (es) | 1998-04-17 | 1999-04-16 | Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto |
| ARP990101771A AR018593A1 (es) | 1998-04-17 | 1999-04-16 | COMPUESTOS TRICICLICOS SUSTITUIDOS, FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE, USO DE DICHO COMPUESTO PARA FABRICAR UN MEDICAMENTO uTIL PARA INHIBIR SELECTIVAMENTE SPLA2 Y ALIVIAR EFECTOS PATOLoGICOS DE ENFERMEDADES RELACIONADAS |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101770A AR018186A1 (es) | 1998-04-17 | 1999-04-16 | Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto |
Country Status (30)
| Country | Link |
|---|---|
| EP (2) | EP0950657B1 (es) |
| JP (2) | JPH11322713A (es) |
| KR (2) | KR19990083232A (es) |
| CN (1) | CN1149193C (es) |
| AR (2) | AR018186A1 (es) |
| AT (2) | ATE268756T1 (es) |
| AU (2) | AU753436B2 (es) |
| BR (2) | BR9902365A (es) |
| CA (2) | CA2269262A1 (es) |
| CO (2) | CO5031247A1 (es) |
| CZ (2) | CZ137099A3 (es) |
| DE (2) | DE69918590T2 (es) |
| DK (1) | DK0950657T3 (es) |
| DZ (1) | DZ2769A1 (es) |
| EA (2) | EA002347B1 (es) |
| ES (2) | ES2226286T3 (es) |
| HU (2) | HUP9901220A3 (es) |
| ID (2) | ID23761A (es) |
| IL (2) | IL129485A0 (es) |
| NO (2) | NO314400B1 (es) |
| NZ (3) | NZ335251A (es) |
| PE (2) | PE20000432A1 (es) |
| PL (2) | PL332566A1 (es) |
| PT (1) | PT950657E (es) |
| SG (2) | SG81976A1 (es) |
| SI (1) | SI0950657T1 (es) |
| TR (2) | TR199900853A2 (es) |
| TW (1) | TWI238160B (es) |
| YU (2) | YU18999A (es) |
| ZA (2) | ZA992771B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1011670A4 (en) * | 1997-08-28 | 2004-10-27 | Lilly Co Eli | PROCESS FOR TREATING NON-RHUMATOID POLYARTHRITIS |
| DZ2769A1 (fr) * | 1998-04-17 | 2003-12-01 | Lilly Co Eli | Composés tricycliques substitués. |
| JP2002542148A (ja) * | 1998-12-21 | 2002-12-10 | イーライ・リリー・アンド・カンパニー | 敗血症の処置のための組み合わせ療法 |
| CA2379208A1 (en) * | 1999-07-19 | 2001-01-25 | Eli Lilly & Company | Spla2 inhibitors |
| US6706752B1 (en) | 1999-07-19 | 2004-03-16 | Eli Lilly And Company | sPLA2 inhibitors |
| US20040102442A1 (en) * | 2000-06-29 | 2004-05-27 | Kohji Hanasaki | Remedies for alzheimer's disease |
| AU2001267825A1 (en) * | 2000-06-29 | 2002-01-08 | Shionogi And Co., Ltd. | Remedies for cirrhosis |
| ATE375171T1 (de) * | 2000-06-29 | 2007-10-15 | Anthera Pharmaceuticals Inc | Heilmittel für krebs |
| CA2413582A1 (en) * | 2000-07-14 | 2002-01-24 | Eli Lilly And Company | Use of a spla2 inhibitor for the treatment of sepsis |
| CA2431028A1 (en) * | 2000-12-18 | 2002-06-27 | Ho-Shen Lin | Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| WO2002079154A1 (en) * | 2001-03-28 | 2002-10-10 | Eli Lilly And Company | Substituted carbazoles as inhibitors of spla2 |
| AUPS282602A0 (en) | 2002-06-07 | 2002-06-27 | Garvan Institute Of Medical Research | Method of inhibiting cell proliferation |
| DE10249055A1 (de) | 2002-10-22 | 2004-05-06 | Bayer Cropscience Ag | 2-Phenyl-2-substituierte-1,3-diketone |
| JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| EP1988098A1 (en) * | 2007-04-27 | 2008-11-05 | AEterna Zentaris GmbH | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors |
| MY161992A (en) | 2008-03-26 | 2017-05-31 | Daiichi Sankyo Co Ltd | Novel tetrahydroisoquinoline derivative |
| PE20091838A1 (es) | 2008-04-09 | 2009-12-18 | Infinity Pharmaceuticals Inc | Inhibidores de amida hidrolasa de acido graso |
| EP2379538A4 (en) | 2009-01-22 | 2013-01-02 | Orchid Res Lab Ltd | HETEROCYCLIC COMPOUNDS AS A PHOSOPHODIESTERASE HEMMER |
| US8541581B2 (en) | 2009-04-07 | 2013-09-24 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| ES2493916T3 (es) | 2009-04-07 | 2014-09-12 | Infinity Pharmaceuticals, Inc. | Inhibidores de hidrolasa de amida de ácidos grasos |
| KR101888026B1 (ko) | 2010-02-03 | 2018-08-13 | 인피니티 파마슈티컬스, 인코포레이티드 | 지방산 아미드 하이드롤라제 저해제 |
| AR088377A1 (es) | 2011-10-20 | 2014-05-28 | Siena Biotech Spa | Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta |
| CN102816107B (zh) * | 2012-08-20 | 2015-06-03 | 东南大学 | 咔唑衍生物及其制备方法与用途 |
| IN2015DN03939A (es) | 2012-11-30 | 2015-10-02 | Ge Healthcare Ltd | |
| US10709798B2 (en) | 2012-11-30 | 2020-07-14 | Ge Healthcare Limited | Crystallization process of tricyclic indole derivatives |
| EP3248230B1 (de) * | 2015-01-20 | 2020-05-06 | cynora GmbH | Verwendung organischer moleküle in optoelektronischen bauelementen |
| CN108707104A (zh) * | 2018-08-07 | 2018-10-26 | 北京恒信卓元科技有限公司 | 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3579534A (en) * | 1969-05-09 | 1971-05-18 | American Cyanamid Co | Tetrahydrocarbazolecarboxylates |
| US3939177A (en) * | 1972-11-22 | 1976-02-17 | Sterling Drug Inc. | 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles |
| US3979391A (en) * | 1972-11-22 | 1976-09-07 | Sterling Drug Inc. | 1,2,3,4-Tetrahydrocarbazoles |
| PT95692A (pt) * | 1989-10-27 | 1991-09-13 | American Home Prod | Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase |
| US5420289A (en) * | 1989-10-27 | 1995-05-30 | American Home Products Corporation | Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase |
| US5472978A (en) * | 1991-07-05 | 1995-12-05 | Merck Sharp & Dohme Ltd. | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| IL109309A (en) * | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| IL109311A0 (en) * | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| DE69610793T2 (de) * | 1995-06-23 | 2001-05-03 | Eli Lilly And Co., Indianapolis | 6-Subsitituierte-1,2,3,4-tetrahydro-9H-Carbazole und 7-substituierte-1OH-Cyclohepta(7,6-B)-Indole |
| ES2159347T3 (es) * | 1995-12-13 | 2001-10-01 | Lilly Co Eli | Naftil-acetamidas como inhibidores de spla2. |
| EA003992B1 (ru) * | 1996-10-30 | 2003-12-25 | Эли Лилли Энд Компани | Замещенные трициклические соединения |
| JP2001517707A (ja) * | 1997-09-26 | 2001-10-09 | イーライ・リリー・アンド・カンパニー | 嚢胞性繊維症の処置方法 |
| JP2001522884A (ja) * | 1997-11-14 | 2001-11-20 | イーライ・リリー・アンド・カンパニー | アルツハイマー病の処置方法 |
| DZ2769A1 (fr) * | 1998-04-17 | 2003-12-01 | Lilly Co Eli | Composés tricycliques substitués. |
-
1999
- 1999-04-14 DZ DZ990069A patent/DZ2769A1/xx active
- 1999-04-15 IL IL12948599A patent/IL129485A0/xx unknown
- 1999-04-15 IL IL12948399A patent/IL129483A0/xx unknown
- 1999-04-15 ID IDP990341D patent/ID23761A/id unknown
- 1999-04-15 ID IDP990340D patent/ID23287A/id unknown
- 1999-04-16 PT PT99302967T patent/PT950657E/pt unknown
- 1999-04-16 YU YU18999A patent/YU18999A/sh unknown
- 1999-04-16 NO NO19991821A patent/NO314400B1/no not_active IP Right Cessation
- 1999-04-16 EA EA199900301A patent/EA002347B1/ru not_active IP Right Cessation
- 1999-04-16 AU AU23817/99A patent/AU753436B2/en not_active Ceased
- 1999-04-16 TR TR1999/00853A patent/TR199900853A2/xx unknown
- 1999-04-16 TW TW088106130A patent/TWI238160B/zh not_active IP Right Cessation
- 1999-04-16 KR KR1019990013436A patent/KR19990083232A/ko not_active Application Discontinuation
- 1999-04-16 NZ NZ335251A patent/NZ335251A/xx unknown
- 1999-04-16 AR ARP990101770A patent/AR018186A1/es not_active Application Discontinuation
- 1999-04-16 AT AT99302941T patent/ATE268756T1/de not_active IP Right Cessation
- 1999-04-16 SI SI9930650T patent/SI0950657T1/xx unknown
- 1999-04-16 TR TR1999/00843A patent/TR199900843A2/xx unknown
- 1999-04-16 HU HU9901220A patent/HUP9901220A3/hu unknown
- 1999-04-16 CO CO99022884A patent/CO5031247A1/es unknown
- 1999-04-16 JP JP11109629A patent/JPH11322713A/ja not_active Withdrawn
- 1999-04-16 AU AU23819/99A patent/AU753547B2/en not_active Ceased
- 1999-04-16 PE PE1999000314A patent/PE20000432A1/es not_active Application Discontinuation
- 1999-04-16 SG SG9901681A patent/SG81976A1/en unknown
- 1999-04-16 KR KR1019990013438A patent/KR100586761B1/ko not_active IP Right Cessation
- 1999-04-16 BR BR9902365-2A patent/BR9902365A/pt not_active IP Right Cessation
- 1999-04-16 EA EA199900303A patent/EA002816B1/ru not_active IP Right Cessation
- 1999-04-16 SG SG9901869A patent/SG81977A1/en unknown
- 1999-04-16 ES ES99302967T patent/ES2226286T3/es not_active Expired - Lifetime
- 1999-04-16 EP EP99302967A patent/EP0950657B1/en not_active Expired - Lifetime
- 1999-04-16 HU HU9901221A patent/HUP9901221A3/hu unknown
- 1999-04-16 CZ CZ991370A patent/CZ137099A3/cs unknown
- 1999-04-16 JP JP15240099A patent/JP4435330B2/ja not_active Expired - Fee Related
- 1999-04-16 DK DK99302967T patent/DK0950657T3/da active
- 1999-04-16 CA CA002269262A patent/CA2269262A1/en not_active Abandoned
- 1999-04-16 NZ NZ507564A patent/NZ507564A/xx unknown
- 1999-04-16 ZA ZA9902771A patent/ZA992771B/xx unknown
- 1999-04-16 PL PL99332566A patent/PL332566A1/xx not_active Application Discontinuation
- 1999-04-16 PL PL99332565A patent/PL332565A1/xx not_active Application Discontinuation
- 1999-04-16 CA CA002269246A patent/CA2269246C/en not_active Expired - Fee Related
- 1999-04-16 CZ CZ991369A patent/CZ136999A3/cs unknown
- 1999-04-16 BR BR9901279-0A patent/BR9901279A/pt not_active IP Right Cessation
- 1999-04-16 NZ NZ335253A patent/NZ335253A/xx unknown
- 1999-04-16 AT AT99302967T patent/ATE271037T1/de active
- 1999-04-16 DE DE69918590T patent/DE69918590T2/de not_active Expired - Lifetime
- 1999-04-16 ZA ZA9902772A patent/ZA992772B/xx unknown
- 1999-04-16 ES ES99302941T patent/ES2222663T3/es not_active Expired - Lifetime
- 1999-04-16 NO NO19991822A patent/NO312240B1/no not_active IP Right Cessation
- 1999-04-16 EP EP99302941A patent/EP0952149B1/en not_active Expired - Lifetime
- 1999-04-16 PE PE1999000320A patent/PE20000476A1/es not_active Application Discontinuation
- 1999-04-16 DE DE69917833T patent/DE69917833T2/de not_active Expired - Lifetime
- 1999-04-16 CN CNB991079574A patent/CN1149193C/zh not_active Expired - Fee Related
- 1999-04-16 YU YU19199A patent/YU19199A/sh unknown
- 1999-04-16 AR ARP990101771A patent/AR018593A1/es active IP Right Grant
- 1999-04-16 CO CO99022897A patent/CO5011054A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR018593A1 (es) | COMPUESTOS TRICICLICOS SUSTITUIDOS, FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE, USO DE DICHO COMPUESTO PARA FABRICAR UN MEDICAMENTO uTIL PARA INHIBIR SELECTIVAMENTE SPLA2 Y ALIVIAR EFECTOS PATOLoGICOS DE ENFERMEDADES RELACIONADAS | |
| CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR018185A1 (es) | Compuestos triciclicos substituidos utiles como inhibidores de la liberacion de acidos grasos mediada por spla2 en mamiferos y uso de dichos compuestos enla fabricacion de composiciones para aliviar los efectos patologicos de enfermedades relacionadas con spla2 | |
| AR059895A1 (es) | Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos | |
| DOP2002000482A (es) | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares | |
| AR008377A1 (es) | Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto | |
| ES2530545T3 (es) | Compuestos tricíclicos inhibidores de la PI3K y métodos de uso | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| ECSP056222A (es) | Derivados de indazolil(indolil)maleimida sustituidoscomo inhibidores de cinasa | |
| UY29437A1 (es) | Nuevos antagonistas de cgrp | |
| MX9300031A (es) | Derivados de piperazina, procedimiento para su preparacion y composicion farmaucetica que los contiene. | |
| PE20050652A1 (es) | Mezclas que contienen estrobilurinas y moduladores de etileno | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| AR064879A1 (es) | Compuesto de piridina condensado | |
| DK0665844T3 (da) | Substituerede benzylaminoquinuclidinforbindelser som antagonister af substans P | |
| CO6220970A2 (es) | Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos | |
| AR076984A1 (es) | Derivados de pirazol oxadiazol | |
| CO4920250A1 (es) | Compuestos heterociclicos utiles en la inhibicion de la spla2 | |
| CO5040004A1 (es) | 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores | |
| AR040763A1 (es) | Profarmacos de la (n-2- piridil-n-2- hidroxicarbonil-etil) - amida del acido 1- metil-2-(4-amidinofenilaminometil)-- benzimidazol-5-il-carboxilico, su preparacion y su utilizacion como medicamentos | |
| AR019256A1 (es) | Utilizacion de derivados tetraciclo[6-6-2-0(2.27).0(9.14)] hexadeca-2(7), 3, 5, 9(14), 10,12-hexaeno, para la preparacion de preparados farmaceuticos conaccion inhibitoria de la fosfolipasa, los referidos derivados y preparado farmaceutico que contiene por lo menos a uno de dichos derivados | |
| AR045100A1 (es) | Pirimidinas sustituidas, procedimiento para su obtencion y su uso en productos pesticidas | |
| ES2036137B1 (es) | Procedimiento para la preparacion de la nueva 1-(3-clorofenil)-4-hidroximetil-7,8-dimetoxi-5h-2,3-benzodiacepina y de sus sales de adicion acida. | |
| AR108535A1 (es) | Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor | |
| AR018652A1 (es) | Inhibidor de catepsina k del tipo pirrolidinona, composicion farmaceuticamente eficaz, usos de dichos compuestos para preparar medicamentos, yprocedimiento para producir dichos inhibidores |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |